01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsNextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsPress ReleasesNextCell in the mediaEventsCompany PresentationsQ&A with CEO
05. ContactContact InformationSubscribe
English
/
Svenska

NextCell Pharma publishes Annual Report 2024/2025

May 4, 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". 

    

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications.  In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years.  A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachmentRead full press release on Cision (external link)
2023-04-18
NextCell invited speaker at European Wound Management Association Meeting in Milan
NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.
NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.
Read moreRead more
2023-03-28
NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted
NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.
Read moreRead more
2023-03-21
NextCell’s CSO elected to ISCT European Regional Secretary
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more
2023-03-07
NextCell’s CSO nominated for ISCT European Regional Secretary
NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been nominated for the position of European Regional Secretary for the International Society for Cell and Gene Therapy.
Read moreRead more
2023-01-26
NextCell publishes its Interim Report 1 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2022 – November 30, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Ma
Read moreRead more
2023-01-25
ProTrans study in COVID-19 expanded to include treatment of severe pneumonia induced by influenza A, RSV and HMP virus
NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has approved the expansion of their Swedish COVID-19 study, to include patients with severe pneumonia due to influenza A, respiratory syncytial virus (RSV) and human metapneumovirus (HMP). The treatment is aimed
Read moreRead more
2023-01-18
Positive feedback on the paediatric plan of the EMA
NextCell Pharma AB ("NextCell") has received positive comments and recommendations for the pediatric investigational plan (PIP) submitted to the Europeans Medicines Agency’s (EMA) pediatric committee (PDCO).
Read moreRead more
2022-12-21
First pediatric patients treated with ProTrans in type-1 diabetes phase II study
NextCell Pharma AB ("NextCell") supports the pediatric diabetes clinical trial conducted at Uppsala University Hospital by Principal Investigator Professor Per-Ola Carlsson with the stromal cell treatment, ProTrans. At the end of October 2022, the Data Safety and Monitoring Board recommended that ph
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept